

Policy #	Policy Name	Type of Change	Brief Description of Policy Change	Reason for Changes
NEW	Hepzato (melphalan)	Positive	On August 14, 2023, the Food and Drug Administration approved HEPZATO KIT (melphalan for Injection/Hepatic Delivery System) containing melphalan (HEPZATO, Delcath Systems, Inc.) as a liver-directed treatment for adult patients with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation.	New FDA Drug/Indication
UM ONC_1193	Revlimid (lenalidomide)	No clinical change	Annual Review	
UM ONC_1275	Dose Optimization Policy	No clinical change	Annual Review	
UM ONC_1331	Calquence (acalabrutinib)	No clinical change	Annual Review	
UM ONC_1392	Reblozyl (luspatercept-aamt)	No clinical change	Annual Review	
UM ONC_1409	Pediatric Treatment Requests	No clinical change	Annual Review	
UM ONC_1228	Xtandi (enzalutamide)	Positive	On June 20, 2023, the Food and Drug Administration approved talazoparib (Talzenna, Pfizer, Inc.) with enzalutamide for homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).	New FDA Drug/Indication
UM ONC_1349	Talzenna (talazoparib)	Positive	On June 20, 2023, the Food and Drug Administration approved talazoparib (Talzenna, Pfizer, Inc.) with enzalutamide for homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).	New FDA Drug/Indication
UM ONC_1469	Imjudo (tremelimumab)	Positive	Review Requested (Internal)	
UM ONC_1314	Imfinzi (durvalumab)	Positive	Review Requested (Internal)	
UM ONC_1133	Erbix (Cetuximab)	Positive	Review Requested (Internal)	
UM ONC_1135	Vectibix (panitumumab)	Positive	Review Requested (Internal)	
UM ONC_1374	Balversa (erdafitinib)	Positive	Review Requested (Internal)	
UM ONC_1433	Jemperli (dostarlimab-gxly)	Positive	Review Requested (Internal)	
UM ONC_1261	Cyramza (ramucirumab)	Positive	Review Requested (Internal)	
UM ONC_1263	Keytruda (pembrolizumab)	Positive	Review Requested (Internal)	
UM ONC_1381	Padcev (enfortumab vedotin-efv)	Positive	Review Requested (Internal)	
UM ONC_1283	Lenvima (lenvatinib)	Positive	Review Requested (Internal)	
UM ONC_1041	LHRH (agonists and antagonists)	Positive	Review Requested (Internal)	